GB201614314D0 - Antibiotic compounds - Google Patents

Antibiotic compounds

Info

Publication number
GB201614314D0
GB201614314D0 GBGB1614314.1A GB201614314A GB201614314D0 GB 201614314 D0 GB201614314 D0 GB 201614314D0 GB 201614314 A GB201614314 A GB 201614314A GB 201614314 D0 GB201614314 D0 GB 201614314D0
Authority
GB
United Kingdom
Prior art keywords
antibiotic compounds
antibiotic
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1614314.1A
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Discuva Ltd
Original Assignee
Discuva Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Discuva Ltd filed Critical Discuva Ltd
Priority to GBGB1614314.1A priority Critical patent/GB201614314D0/en
Publication of GB201614314D0 publication Critical patent/GB201614314D0/en
Priority to US16/327,286 priority patent/US20190194179A1/en
Priority to CA3034000A priority patent/CA3034000A1/en
Priority to MX2019001978A priority patent/MX2019001978A/es
Priority to JP2019510688A priority patent/JP2019528291A/ja
Priority to EP17761308.0A priority patent/EP3500567A1/en
Priority to CN201780063473.8A priority patent/CN109923111A/zh
Priority to EA201990551A priority patent/EA201990551A1/ru
Priority to AU2017316742A priority patent/AU2017316742A1/en
Priority to KR1020197008269A priority patent/KR20190046894A/ko
Priority to SG11201901374WA priority patent/SG11201901374WA/en
Priority to BR112019003427-7A priority patent/BR112019003427A2/pt
Priority to PCT/GB2017/052478 priority patent/WO2018037223A1/en
Priority to PH12019500360A priority patent/PH12019500360A1/en
Priority to CONC2019/0002624A priority patent/CO2019002624A2/es
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425Thiazoles
    • A61K31/427Thiazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/433Thidiazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355Non-condensed oxazines and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/58Benzoxazoles; Hydrogenated benzoxazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
GBGB1614314.1A 2016-08-22 2016-08-22 Antibiotic compounds Ceased GB201614314D0 (en)

Priority Applications (15)

Application Number Priority Date Filing Date Title
GBGB1614314.1A GB201614314D0 (en) 2016-08-22 2016-08-22 Antibiotic compounds
PCT/GB2017/052478 WO2018037223A1 (en) 2016-08-22 2017-08-22 Antibiotic compounds
CN201780063473.8A CN109923111A (zh) 2016-08-22 2017-08-22 抗生素化合物
AU2017316742A AU2017316742A1 (en) 2016-08-22 2017-08-22 Antibiotic compounds
MX2019001978A MX2019001978A (es) 2016-08-22 2017-08-22 Compuestos antibioticos.
JP2019510688A JP2019528291A (ja) 2016-08-22 2017-08-22 抗生化合物
EP17761308.0A EP3500567A1 (en) 2016-08-22 2017-08-22 Antibiotic compounds
US16/327,286 US20190194179A1 (en) 2016-08-22 2017-08-22 Antibiotic compounds
EA201990551A EA201990551A1 (ru) 2016-08-22 2017-08-22 Антибиотические соединения
CA3034000A CA3034000A1 (en) 2016-08-22 2017-08-22 Antibiotic compounds
KR1020197008269A KR20190046894A (ko) 2016-08-22 2017-08-22 항생제 화합물
SG11201901374WA SG11201901374WA (en) 2016-08-22 2017-08-22 Antibiotic compounds
BR112019003427-7A BR112019003427A2 (pt) 2016-08-22 2017-08-22 compostos antibióticos
PH12019500360A PH12019500360A1 (en) 2016-08-22 2019-02-20 Antibiotic compounds
CONC2019/0002624A CO2019002624A2 (es) 2016-08-22 2019-03-21 Compuestos antibióticos

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1614314.1A GB201614314D0 (en) 2016-08-22 2016-08-22 Antibiotic compounds

Publications (1)

Publication Number Publication Date
GB201614314D0 true GB201614314D0 (en) 2016-10-05

Family

ID=57045563

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1614314.1A Ceased GB201614314D0 (en) 2016-08-22 2016-08-22 Antibiotic compounds

Country Status (15)

Country Link
US (1) US20190194179A1 (https=)
EP (1) EP3500567A1 (https=)
JP (1) JP2019528291A (https=)
KR (1) KR20190046894A (https=)
CN (1) CN109923111A (https=)
AU (1) AU2017316742A1 (https=)
BR (1) BR112019003427A2 (https=)
CA (1) CA3034000A1 (https=)
CO (1) CO2019002624A2 (https=)
EA (1) EA201990551A1 (https=)
GB (1) GB201614314D0 (https=)
MX (1) MX2019001978A (https=)
PH (1) PH12019500360A1 (https=)
SG (1) SG11201901374WA (https=)
WO (1) WO2018037223A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7503051B2 (ja) 2018-10-11 2024-06-19 バイエル・アクチエンゲゼルシヤフト イミダゾール誘導体の製造方法
EP3636645A1 (de) 2018-10-11 2020-04-15 Bayer Aktiengesellschaft Verfahren zur herstellung schwefel-substituierter pyridinderivate
TWI841671B (zh) 2019-01-24 2024-05-11 日商第一三共股份有限公司 具有取代基之脲化合物
US20220125763A1 (en) 2019-02-22 2022-04-28 Anifera Limited Compositions providing enhanced antibacterial activity against gram-positive bacteria and use thereof
CN111808093B (zh) * 2019-04-12 2023-05-16 中国医学科学院医药生物技术研究所 一种新德里金属-β-内酰胺酶-1抑制剂
WO2020210339A1 (en) 2019-04-12 2020-10-15 Mitobridge, Inc. Hmox1 inducers
US12528798B2 (en) 2019-10-29 2026-01-20 Lg Chem, Ltd. Compound for crop protectant
WO2022108354A1 (ko) * 2020-11-19 2022-05-27 주식회사 에이엔제이사이언스 신규 화합물, 이의 제조방법 및 이를 포함하는 항생제 조성물
CN113185475A (zh) * 2021-04-29 2021-07-30 江苏永凯化学有限公司 一种高效低污染的精恶唑禾草灵生产工艺
CN117043141A (zh) * 2021-05-31 2023-11-10 江苏亚虹医药科技股份有限公司 7-硝基-8-羟基喹啉衍生物、其制备方法及其医药用途
KR102754999B1 (ko) * 2022-01-06 2025-01-21 충남대학교산학협력단 신규한 화합물 및 이를 포함하는 결핵균 또는 비결핵항산균 감염질환 치료용 약제학적 조성물
WO2023234970A1 (en) * 2022-06-01 2023-12-07 KUDA Therapeutics, Inc. Imidazopyridine and oxazolopyridine derivatives and analogs thereof, methods of preparation thereof, methods of hif-1/2a pathway inhibition, and induction of ferroptosis
WO2024130173A1 (en) * 2022-12-16 2024-06-20 Immvention Therapeutix Benzimidazole derivatives
KR102840252B1 (ko) * 2023-04-27 2025-07-30 한국화학연구원 시아노벤즈이미다졸 유도체, 약제학적으로 허용가능한 염, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물
CN117003710A (zh) * 2023-07-19 2023-11-07 镇江先锋植保科技有限公司 一种2-巯基-6-氯苯并恶唑的制备方法
CN121889378A (zh) * 2023-09-01 2026-04-17 英孚欣治疗生物技术公司 取代的苯并噁唑基氨基苯并噁唑

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8604217B2 (en) * 2009-11-12 2013-12-10 Selvita S.A. Compound, a process for its preparation, a pharmaceutical composition, use of a compound, a method for modulating or regulating serine/threonine kinases and a serine/threonine kinases modulating agent
JP5786402B2 (ja) * 2011-03-29 2015-09-30 コニカミノルタ株式会社 光学フィルム、及びそれを用いた偏光板、液晶表示装置
WO2016039939A1 (en) * 2014-09-09 2016-03-17 Ptc Therapeutics, Inc. Bicyclic and tricyclic substituted 2-pyridinone antibacterial compounds

Also Published As

Publication number Publication date
WO2018037223A1 (en) 2018-03-01
CA3034000A1 (en) 2018-03-01
EP3500567A1 (en) 2019-06-26
SG11201901374WA (en) 2019-03-28
AU2017316742A1 (en) 2019-04-11
CO2019002624A2 (es) 2019-05-31
KR20190046894A (ko) 2019-05-07
JP2019528291A (ja) 2019-10-10
US20190194179A1 (en) 2019-06-27
MX2019001978A (es) 2019-08-01
BR112019003427A2 (pt) 2019-05-21
PH12019500360A1 (en) 2019-11-11
CN109923111A (zh) 2019-06-21
EA201990551A1 (ru) 2019-12-30

Similar Documents

Publication Publication Date Title
IL256391A (en) Antibacterial compounds
GB201614314D0 (en) Antibiotic compounds
GB201602934D0 (en) Compounds
GB201620119D0 (en) Compounds
GB201619694D0 (en) Compounds
GB201610854D0 (en) Compounds
GB201604020D0 (en) Compounds
GB201604027D0 (en) Compounds
GB201613946D0 (en) Compounds
GB201608777D0 (en) Compounds
GB201604022D0 (en) Compounds
GB201604030D0 (en) Compounds
GB201516614D0 (en) Antibacterial compounds
GB201622362D0 (en) Compounds
GB201602235D0 (en) Antibacterial compounds
GB201604029D0 (en) Compounds
GB201604031D0 (en) Compounds
GB201718284D0 (en) Antibiotic compounds
GB201511858D0 (en) Antibiotic compounds
HK40010325A (en) Antibiotic compounds
GB201616456D0 (en) Antibacterial compounds
GB201616460D0 (en) Antibacterial compounds
GB201613866D0 (en) Antibacterial compounds
GB201619471D0 (en) Antibiotics
GB201621762D0 (en) Herbicial Compounds

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)